Clinical evaluation of functional visual acuity after implantation of a monofocal extended-depth-of-focus intraocular lens with an addition of +1.25 dpt

Session Details

Session Title: Extended-Depth-Of-Focus IOLs II

Session Date/Time: Monday 16/09/2019 | 14:00-16:00

Paper Time: 14:06

Venue: Free Paper Forum: Podium 1

First Author: : R.Lucchesi GERMANY

Co Author(s): :    F. Kretz   I. Kaiser   C. Herbers   J. Winters   M. Moftah   S. Abdassalam              

Abstract Details

Purpose:

A prospective study to evaluate the refractive and functional results after implantation of a monofocal Extended Depth of Focus (EDoF) intraocular lens in cataract patients.

Setting:

Augentagesklnik Rheine, Germany

Methods:

In a prospective study 12 eyes (6 patients) were examined 1 - 2, 7 - 14, 30 - 60, 80 - 100, 120 - 180 days after uncomplicated bilateral cataract surgery with implantation of a monofocal EDoF IOL (ME4 Xact® Advanced Vision Science. Inc., USA). The target refraction was emmetropia for both eyes. Postoperatively we evaluated the visual acuity (UDVA & DCVA [5m], UIVA & DCIVA [50cm, 60cm, 70cm]), defocus curve, contrast vision (mesopic & photopic with and without glare), the patient satisfaction (VF 14 - QOL Questionnaire) and visual effects assessments.

Results:

Postoperatively, after 120 - 180 days we observed an average spherical equivalent of -0.04 [+/-0.5]. The mean visual acuity was 0.02 [+/-0.05] (5m UDVA); -0.09 [+/-0.06] (5m DCVA); 0.4 [+/-0.19] (50cm UIVA); 0.41 [+/-0.14] (50cm DCIVA); 0.3 [+/-0.17] (60cm UIVA); 0.29 [+/-0.15] (60cm DCIVA); 0.22 [+/-0.17] (70cm UIVA); 0.21 [+/-0.18]. The binocular defocus curve showed a visual acuity of ≤0,2logMAR in the range of +1.0 to -1.5 dpt.

Conclusions:

The bilateral implantation of a monofocal EDoF IOL with an addition of +1.25 dpt shows a good visual acuity for the distance with a good intermediate visual acuity up to 70 cm, so there is a spectacle independence for these distances.

Financial Disclosure:

gains financially from competing product or procedure, travel has been funded, fully or partially, by a competing company, travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, research is funded, fully or partially, by a competing company, research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, receives non monetary benefits from a competing company, receives non monetary benefits from a company producing, developing or supplying the product or procedure presented, receives consulting fees, retainer, or contract payments from a competing company, receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, is employed by a competing company, has significant investment interest in a company producing, developing or supplying product or procedure presented